Mirikizumab
Mirikizumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Colitis, Ulcerative、Crohn Disease、Ulcerative Colitis、Ulcerative Colitis Chronic。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
14 项
全球在招研究
8 项
已进入 III/IV 期
21 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Eli Lilly and Company
- Alimentiv Inc.
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- University of North Carolina, Chapel Hill
- University Hospital Schleswig-Holstein
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、加拿大、法国、奥地利、比利时、Brazil、Israel、意大利、日本、荷兰、挪威、Poland
正在招募患者的 Mirikizumab 研究
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
IV 期招募中美国加拿大NCT06997965Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
IV 期招募中法国NCT07292012A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
III 期招募中美国奥地利比利时BrazilNCT05509777A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
IV 期招募中美国加拿大丹麦德国NCT07612267A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
II 期招募中美国比利时Brazil加拿大NCT07483099A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
I 期招募中美国NCT07446101Ibd CAncer and seRious Infections in France (I-CARE 2)
不适用招募中法国NCT06089590Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
III 期招募中美国奥地利比利时BrazilNCT06937099COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
不适用招募中美国NCT07198113LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
II 期招募中美国奥地利Brazil加拿大NCT07186101Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
III 期招募中美国奥地利比利时BrazilNCT06937086Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis
IV 期招募中德国NCT07235904A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
III 期招募中美国奥地利比利时BrazilNCT04844606A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
II 期招募中美国比利时Brazil加拿大NCT07483073
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。